New Delhi: Nephro Care IPO is all set to be listed on Friday, July 05, 2024. In an exclusive interview with Money9, Anshul Jain, Lakhsmishree Investments & Sec, said, Nephro Care IPO allottees can hold on to the stock for the long term. He, however, said if the shares have a bumper listing (as the stock’s latest GMP signifies), then, it may take time of 4-6 months to absorb gains made. While, Nephro Care IPO GMP today has almost doubled from the levels seen at day three of the stake sale process.
Also read: Why Modi 3.0 first Budget may give stock market investors a reason to smile!
Nephro Care IPO GMP today
According to ‘InvestorGain’, Nephro Care IPO GMP today stood at Rs 235 ahead of listing. Although, considering upper limit of Nephro Care IPO price band of Rs 85 to Rs 90 and the latest grey market premium, Nephro Care IPO listing gains of 260 per cent can be expected. Nephro Care IPO listings will be made on NSE SME. However, it may be noted that the National Stock Exchange (NSE) on July 4 announced to introduce an overall capping of 90 per cent on the opening price on the issue price of SME IPOs during the pre-opening session.
Nephro Care IPO Subscription Status
According to ‘iPOWatch’, Nephro Care IPO subscription status was a bumper hit as it reached whopping 715X of its total issue size of Rs 41 crore by the final day of the stake sale process. Nephro Care IPO Retail investors’ subscription status was 634 times. While, Nephro Care IPO NII category was subscribed 1,787 times.
Also read: Men vs Women who handles stock market volatility better?
Nephro Care IPO allotment finalisation date was on July 03, 2024. Shares were credited to the demat accounts of IPO allottes on July 04. Nephro Care IPO opene dfor subscription on June 28 and ended on 2nd July.
Nephro Care India Limited is a healthcare provider that specialises in the treatment of kidney-related diseases. The healthcare service provider enjoys a reputation for state of the art treatment of chronic kidney diseases.
(Disclaimer: This article is only meant to provide information. News9live.com does not recommend buying or selling shares or subscriptions of any IPO and Mutual Funds.)
Nephro Care IPO listing: Anshul Jain, Lakhsmishree Investments & Sec, advised Nephro Care shareholders to remain invested in the stock for the long term. The Nephro shares are expected to have a bumper listing as the GMP is very high. Markets Business News – Personal Finance News, Share Market News, BSE/NSE News, Stock Exchange News Today
